Industry Hails Access Implications As FTC Promises PBM Probe
Follows AAM And Biosimilars Forum’s Calls For Action Over Behaviors That Restrict Access
The US FTC’s announcement of an inquiry into PBMs will be music to the ears of the country’s generics and biosimilars industry, which has long called for action on abusive practices that undermine access.
